
EARNINGS CALL 3020 hapvida

3Q20 Highlights



Main financial and operational indicators – Hapvida¹





Net Revenue

+61.6%



MLR ex-SUS

-0.6 p.p.



EBITDA

+93.8%



EBITDA Margin

+4.0 p.p.



Total Beneficiaries

+56.9%

M&A Transactions



On going search for good assets and focus on inorganic growth



July 15, 2020

- São José dos Campos/SP
- 104 beds
- 2 hospitals
- 51 thousand lives



September 8, 2020

- Belo Horizonte/MG
- 273 beds
- 3 hospitals + 1 day hospital
- 273 thousand lives



September 8, 2020

- Goiânia/GO
- 18 thousand lives



September 8, 2020

Lease of the Hospital Sinhá Junqueira in Ribeirão Preto/MG



September 18, 2020

- Anápolis/GO
- 53 beds



September 18, 2020

- Anápolis/GO and Goianésia/GO
- 18 thousand lives



September 28, 2020

- Rio Claro/SP
- 73 beds
- 1 hospital
- 5,5 thousand lives



November 9, 2020

- Belo Horizonte/MG, Brasília/DF and Montes Claros/MG
- 125 thousand lives

Status M&A 2019





Processing incorporation



Systems implemented




Closing in November/20




Waiting for approval

Hapvida's Infrastructure









Beneficiaries






Average Monthly Ticket





Net Revenue






Medical Costs and Medical Loss Ratio



Total Medical Costs x MLR



0 VERTICALIZATION¹ 96% 87% 84% 80% Medical Hospitalizations Exams General **Appointments MAIN VARIATIONS** + Representativeness of costs in the own network (+2.2 p.p. in 3Q20) - Procedures in the accredited network (R\$ 55.0M 3Q20 and R\$ 149.5M 9M20) + Expenses with new units (R\$ 5.6M 3Q20 and R\$ 24.2M 9M20) + Costs related to Covid-19 (R\$ 32.3M 3Q20 and R\$ 80.6M 9M20)

+ Personnel expenses (R\$ 16.2M 3Q20 and R\$ 47.5M 9M20)


- SUS provision (R\$ 13.5M 3Q20 vs R\$ 24.6M 3Q19)

^{1%} calculated by the volume of appointments made in our own network in the 3Q20

SUS Reimbursement




Reimbursement Flow




Reimbursement Breakdown

In R\$ Milllon



Operational Expenses







¹ Comparison between 3Q20 and 1Q20

EBITDA and Net Income











Free Cash Flow and Capex





Disclaimer



This material reflects management's expectations and may contain estimates related to future events. Any information. data. forecasts or future plans herein refer to estimates. and therefore can not be taken as concrete evidence or a promise to the market. Hapvida is not responsible for investment operations or decisions taken based on the information herein. These estimates are subject to change without prior notice.

This material has been prepared by Hapvida Participações e Investimentos S.A. ("Hapvida" or the "Company") in accordance with the highest national and international standards. and it includes certain forward-looking statements that are primarily based on Hapvida's current expectations and projections of future events and financial trends that currently affect or may affect the company's business. and therefore they are not guarantees of future performance. They are based on management's expectations and involve a number of risks and uncertainties that could lead the company's financial situation and operating results to differ materially from those expressed in Hapvida's forward-looking statements.

Hapvida assumes no obligation to publicly update or revise any forward-looking statements. This material is disclosed solely for informational purposes and should not be construed as a request or an offer to buy or sell any shares or related financial instruments. Accordingly, this presentation is not a recommendation of investment and should not be considered as such. It is not related to specific investment objectives, financial situation or particular needs of any recipient. Neither does it make a statement or provide a guarantee, either express or implied, related to the accuracy, completeness or reliability of the information herein. This presentation should not be regarded as a substitute to the recipients' judgment. Any opinion expressed herein is subject to change without prior notice and Hapvida does not assume the obligation to update or revise them.